Article

The COVID-19 Pandemic Has Disrupted Cancer Trials

Author(s):

Aislinn Antrim, Assistant Editor

Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trials.

Pharmacy Times® interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers and medical director at Ann B. Barshinger Cancer Institute, Penn Medicine in Lancaster PA about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trial.

The full conversation can be found in the video above.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
Related Content
Chronic myeloid leukemia in chronic phase -- Image credit: MdBabul | stock.adobe.com
Published: October 29th 2024 | Updated: October 29th 2024

FDA Grants Accelerated Approval to Asciminib for Adult Patients With Newly Diagnosed Ph+ CML-CP

Gillian McGovern, Assistant Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

USP, American Pharmacists Month
October 29th 2024

American Pharmacists Month: Stephanie Y. Crawford, PhD, MPH, on Mentorship, Health Equity, and the Expanding Role of Pharmacists

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Pain related to bile duct cancer -- Image credit: vachiravit | stock.adobe.com
October 29th 2024

Tucatinib With Trastuzumab Shows Positive Effects in Patients With Bile Duct Cancer

Gillian McGovern, Assistant Editor
FDA, Leukemia, arthritis, pediatric | Image Credit: stockPhotoPro - stock.adobe.com
October 29th 2024

FDA Expands Methotrexate Indication to Included Children With Acute Lymphoblastic Leukemia

Ashley Gallagher, Associate Editor